Vaxcyte, VAX-31, OPUS-1, Pneumococcal Vaccine, Pneumococcal Conjugate Vaccine, PCV, Phase 3, Clinical Trial, Invasive Pneumococcal Disease, Pneumococcal Pneumonia

SAN CARLOS, Calif. — October 5, 2026 Vaxcyte, Inc. reported positive topline results from the pivotal OPUS-1 Phase 3...